Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as seen in the results of a large phase 3 clinical trial reported today at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in San Francisco, California. Saby George, MD, FACP, Professor of Oncology and Medicine and Director of Network Clinical Trials at Roswell Park Comprehensive Cancer Center, will deliver an oral abstract summarizing the findings of “A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants with Previously Treated Clear Cell Renal Carcinoma That Is Advanced or Has Spread (CheckMate-67T)” (NCT04810078).

The U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designation to Canget BioTekpharma LLC for FL118, a drug candidate developed at Roswell Park Comprehensive Cancer Center, as a possible treatment for pancreatic cancer.

In recognition of his dedication toward advancements in lung cancer care as well as his contributions as a valued mentor, Roswell Park Comprehensive Cancer Center Chair of Thoracic Surgery, Sai Yendamuri, MD, MBA, FACS, has recently been honored with prestigious leadership roles, awards, and grant funding from both local and national organizations.

Following a national search, Roswell Park Comprehensive Cancer Center has selected George T. “Buddy” Hickman as its new Chief Digital & Information Officer. Hickman succeeds Tom Furlani, PhD, who retires this month.